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hepatitis B patients after multiple treatment
failures in real-life practice
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Aim: To evaluate the efficacy and safety of Entecavir (ETV) plus adefovir (ADV) for chronic hepatitis B (CHB) patients
after multiple nucleos(t)ide analogue (NAs) failure treatment.
Methods: Hepatitis B e antigen (HBeAg)-positive patients who had a suboptimal response or developed resistance
to two or more previous NAs treatments were included, and all subjects were treated with ETV in combination with
ADV for ≥ 24 months. Complete virologic response (CVR) was defined as an undetectability of serum hepatitis B
virus (HBV) DNA level during treatment. Safety assessment was based on the increasing of serum creatinine and
creatine kinase levels.
Results: A total of 45 eligible patients were included. Twenty-five patients had been treated with lamivudine (LAM)
or telbivudine (LdT) and developed genotypic resistance. Resistance to ADV was present in 18 patients and 4
patients had a suboptimal response to ETV. Two patients had a resistance to both LAM and ADV. The cumulative
probabilities of CVR at 12 and 24 months of ETV + ADV treatment were 88.9% (40/45) and 97.8% (44/45),
respectively. Although one patient failed to achieve CVR, its serum HBV DNA level decreased by 3.3 log copies/mL
after 24 months of combination therapy. The cumulative probability of HBeAg seroconversion was 15.6% (7/45) and
26.7% (12/45) at 12 and 24 months of treatment, respectively. History of prior exposure to specific NAs did not
make a difference to ETV + ADV treatment outcome. There were no significant adverse events related to ETV + ADV
therapy observed in the study subjects.
Conclusion: ETV + ADV can be used as an effective and safe rescue therapy in patients after multiple NA therapy
failures, especially in the areas where tenofovir is not yet available.
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About a quarter of the world’s population have been
infected with hepatitis B virus (HBV), including 350 mil-
lion patients with chronic hepatitis B (CHB); and about
15% to 25% of CHB patients would progress to life-
threatening liver disease including cirrhosis and hepato-
cellular carcinoma [1]. Nucleos(t)ide analogues (NAs) as
an important class of antiviral drugs have changed the
treatment paradigm and prognosis of CHB [2]. However,
the development of antiviral resistance has become a
threat of NAs therapy [3,4], and an increasing number of* Correspondence: gailichina23@hotmail.com
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reproduction in any medium, provided the orpatients experience multiple NAs treatment failures, espe-
cially when they are sequentially treated with NAs that
have low genetic barrier and similar characteristics [5-7].
In past decade in China, many CHB patients have under-
gone sequential treatment with lamivudine (LAM), adefovir
dipivoxil (ADV), telbivudine (LdT) and/or entecavir (ETV)
at 1 mg to manage antiviral resistance or insufficient
suppression of HBV DNA. In fact, majority of multidrug
failure were developed in patients who switched to ADV
monotherapy for LAM refractory, and the virological and
biochemical outcomes of single ETV salvage therapy were
not satisfactory [8]. And the multidrug failures or resist-
ance have begun to emerge as an important and difficult
issue for clinicians [9].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the development of drug resistance was associated with
viral relapse, biochemical breakthrough, clinical deteri-
oration, and even losing of favorable effects obtained
by previous NAs treatment. Thus, to achieve sustained
suppression of HBV DNA replication and remission of
liver disease, successful management of CHB patients
who developed treatment failure due to antiviral resist-
ance or incomplete inhibition of viral replication is
critical [9,10].
Recently, the increasing evidence suggests that combin-
ation therapy could effectively suppress viral replication
and significantly delay or prevent the emergent of drug
resistance of HBV strains, and combination therapy has
become a potentially attractive therapeutic option in man-
agement of refractory CHB patients [11-16]. However, as
compared to other antiretroviral therapies, the experience
of combination antiviral therapy for CHB after multiple
failures is relatively few at present. Recently, the com-
bination of ETV and ADV has been widely concerned;
however, its efficacy in patients who had a suboptimal
response or developed resistance to two or more previous
NAs treatments is not well known.
In this study, we evaluated the efficacy and safety of
the combination of ETV plus ADV in CHB patients after
the failure of multiple NA therapies, and the data gener-
ated in this study were anticipated to provide researchers
and practitioners with more information regarding the
management of CHB patients after multiple failures.
Materials and methods
Subjects
CHB patients with failures of two or more previous NAs
therapies were treated with 0.5 mg of ETV (Bristol-
Myers Squibb) plus 10 mg of ADV (GlaxoSmithKline)
daily for at least 24 months. Failures of previous NAs
therapies included suboptimal viral suppression (serum
HBV DNA level > 10 000 copies/mL despite continued
therapy for more than 1 year) or the development of re-
sistance. Exclusion criteria were coinfection with human
immunodeficiency virus or hepatitis C virus, and history
of underlying renal problems. The study protocol was
approved by the ethics committee of Chengdu Military
General Hospital, and was conducted in accordance with
the principles of the Declaration of Helsinki.
Laboratory and clinical assessment
Serum HBV DNA, hepatitis B e antigen (HBeAg), anti-
hepatitis B e antibody (Anti-HBe), alanine aminotransfer-
ase, creatinine and creatine kinase levels were detected
every 3 or 6 months. Serum HBV DNA level was deter-
mined by real-time polymerase chain reaction assay(DA
AN Gene Co.,Ltd., Guangzhou, China), which has a lower
limit of detection at 500 copies/mL. Serum HBeAg andAnti-HBe statues were measured using Enzyme-Linked
Immunosorbent Assay (Intec Stone, China). To identify
mutations associated with resistance in the gene encoding
HBV polymerase, PCR amplification and direct sequen-
cing was performed.
Definition of treatment response
The mean reduction of serum HBV DNA level was
assessed during treatment. Complete virological response
(CVR) was defined as a decrease of serum HBV DNA
≤500 copies/mL. The primary non-response was defined
as a decrease of serum HBV DNA of less than 2 log
copies/mL at 24 weeks of therapy. Viral breakthrough was
defined as an increase of HBV DNA > 1 log copies/mL
from nadir during ETV +ADV treatment. HBeAg sero-
conversion was defined as loss of HBeAg and appearance
of anti-HBe on two occasions at least.
Statistical analysis
To describe continuous variables with normal distri-
butions, the mean ± standard deviation was used. Continu-
ous variables without normal distributions were expressed
as the median with range. Cumulative probability of CVR
during the treatment period was calculated using the
Kaplan-Meier method. P values less than 0.05 were consid-
ered statistically significant. All data were analyzed using
SPSS 15.0 (Chicago, IL, United States).
Results
Baseline characteristics of the study subjects
A total of 52 patients with failures of two or more previ-
ous NAs therapies were screened, of which 7 patients were
excluded by underlying renal problems, and the remaining
45 patients were included in the study. Detailed demo-
graphics of those 45 included patients are presented in
Table 1. In this cohort, the mean age was 38.64 ± 5.82 years
and 71.1% of them were male. The mean baseline serum
HBV DNA level was 5.4 ± 1.3 log copies/mL. Twenty-
three patients had been treated with LAM (N= 16) or
telbivudine (LdT) (N = 7) and developed genotypic resist-
ance. Resistance to ADV was present in 18 patients, and 4
patients had a suboptimal virological response to ETV.
Two patients had a resistance to both LAM and ADV.
The median treatment duration of ETV +ADV combin-
ation therapy was 30 months (range 23 to 38 months).
Virological response
The probability of CVR was 88.9% (40/45) at 12 months
and 97.8% (44/45) after 24 months of treatment (Figure 1A).
In this study, no patient developed primary non-response
or viral breakthrough during follow-up. Though one
patient did not achieve CVR, its serum HBV DNA level
had decreased by 3.3 log copies/mL after 24 months of
combination therapy.
Table 1 The baseline demographics of patients in this
study
Characteristic Value
Gender (Male/Female, n/n) 32/13
Age, yr 38.64 ± 5.82
Serum ALT (IU/mL) 134.53 ± 32.61
Serum HBV DNA (log 10 copies/mL) 5.4 ± 1.3
LAM/LdT-resistant mutation, n(%) 23(51.11%)
rtM204I 7




RtN236T + rtA181T/V 4
LAM + ADV resistance 2(4.44%)
Suboptimal response to ETV 4(8.89%)
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of CVR according to prior exposures to different anti-
viral agents and genotypic resistance profile, the CVR
rates were compared according to these variables using
a log-rank test. There were no significant differences
between patients with prior exposure to LAM and ADV
vs LAM, ADV, and ETV (P =0.503). Genotypic resist-
ance to ADV (rtA181V/T or rtN236T) and resistance to
LAM/LdT did not affect CVR rates (P =0.876 and 0.104,
respectively).
Biochemical and serological responses
Cumulative probability of ALT normalization and HBeAg
clearance was calculated with the Kaplan-Meier method.
After 24 months of ETV +ADV combination therapy, allFigure 1 Curative efficacy. The percentages for complete virological resppatients obtained ALT normalization; and the rate of
HBeAg/Anti-HBe seroconversion was 15.6% (7/45) at
12 months and 26.7% (12/45) at 24 months of treatment
(Figure 1B).
Adverse events
No patient developed renal toxicity and creatine kinase
increasing, and there were no other adverse events re-
lated to ETV or ADV therapy observed in the subjects.
Discussion
The management of CHB has improved markedly over
the past decade, primarily due to the development of
effective antiviral agents. Recently, the sustained suppres-
sion of HBV DNA replication in vivo has been shown to
be associated with the prevention of disease progression
and complications of chronic HBV infection [1]. However,
more and more evidence showed that sequential therapies
with multiple NAs with low genetic barrier, significantly
promoted the selection of drug-resistant strains of HBV
and frequently leaded to viral breakthrough or inadequate
viral response, which would inevitably not only diminish
the beneficial effects of previous therapy but also limit
their future therapeutic options [6,17]. Currently, NAs
multiple failures are becoming a global clinical and public
health problem, which is urgently needed to be solved.
A newly established concept in the management of NAs
treatment failures is the superiority of add-on therapy
rather than switch-to therapy [18]. However, the data on
the efficacy of combination therapy for the patients with
multidrug refractoriness is still limited. This study was a
‘real-world’ assessment of ETV +ADV salvage therapy in
patients with developed resistance or suboptimal response
to two or more previous NAs treatment. Our results dem-
onstrated that ETV +ADV could induce ideal complete
virologic response and HBeAg seroconversion, suggestingonse (A) and HBeAg/Anti-HBe seroconversion (B).
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apy in CHB patients after multiple NAs therapy failures.
In this cohort, majority of the patients were exposure
to sequential LAM and ADV treatment, and 9 patients
had a resistance to both LAM and ADV. Though LAM +
ADV has been widely used for rescue therapy in past years
for those patients [5,13], patients with sequential LAM
and ADV resistance had resistant mutations on the same
HBV genome, which anticipated that the combination
therapy of LAM+ADV might be unsatisfactory for the
CHB patients with genotypic resistance associated with
sequential LAM and ADV treatment. Indeed, recent data
also showed that the combination therapy of LAM+ADV
was not effective and was inferior to ETV containing treat-
ment in suppressing HBV DNA [14], which indicated that
ETV based combination therapy would be more superior
to the LAM+ADV combination therapy in management
of LAM- or ADV- resistant patients. And this superiority
of ETV +ADV could be explained by the effect of ETV
against ADV resistant mutation and the effect of ADV
against LAM resistant mutation. In present study, we also
found that ETV + ADV combination therapy showed ideal
efficacy in HBV DNA suppression over 24 months in pa-
tients after LAM and ADV therapy failures, and this find-
ing also supported the superior efficacy of ETV +ADV
combination therapy in a certain degree [19].
In this study, there was one patient did not achieve
CVR with ETV + ADV combination treatment. Further
analysis revealed that he had a resistance to both LAM
and ADV prior to ETV + ADV treatment. In fact, some
previous reports had suggested that ETV + ADV com-
bination therapy had lower efficacy in patients with both
LAM and ADV genotypic resistant mutations as com-
pared to patients with LAM single or ADV single resist-
ant mutations [20,21].
Owing to the potent antiviral activity and high genetic
barrier to resistance, ETV is now recommended as a
first-line therapy for HBV infected patients in all
recently published guidelines. However, there were also
some patients responded poorly to ETV monotherapy
[11], and the optimization therapy for ETV failure is
concerned recently. In this study, there were also 4 pa-
tients with suboptimal response to ETV, and all of them
had been exposure to sequential LAM and ETV treat-
ment. As we know, there is cross-resistance site of HBV
between LAM and ETV, and ETV was less effective in
LAM-resistant patients, either for rtM204I or rtL180 M
plus rtM204V mutants [22]. In present study, we inter-
ested found that the add-on of ADV treatment could
significantly inhibit the viral replication to undetectable
level for all 4 patients with suboptimal response to
sequential LAM and ETV treatment.
In this study, all patients were well tolerated, and no
significant adverse events related to ETV + ADV therapyobserved. And the safety profile of ETV + ADV combin-
ation therapy for CHB patients in this cohort was similar
to the profile reported in other studies.
Limitations of this study are the small sample size and
relatively short observation duration. Thus, clinical trials
with large sample size and long term follow-up are needed
to confirm our findings. Because of the unavailability of
tenofovir in China, we could not evaluate the efficacy of
tenofovir or the combination therapy including tenofovir
in for CHB patients after multiple failures, and further
studies is needed to determine their superiority.
In conclusion, in CHB patients after multiple NA ther-
apy failures, ETV +ADV can be used as an effective and
safe rescue therapy, especially in the areas where tenofovir
is not yet available.
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